UK Parliamentarians Call For A New, Internationally Competitive Pricing System
Executive Summary
Much-needed investment could be lost if the “uncompetitive” sales rebate rate is not reduced as part of talks on a new UK drug pricing scheme, some parliamentarians are warning.
You may also be interested in...
Investment In Medicines Manufacturing Must Be UK Priority
New report on UK medicines manufacturing advises the government to improve voluntary scheme on medicine pricing to drive growth.
Lords Call For UK Government To Secure A ‘Growth’ Pricing Deal With Pharma
The House of Lords held a debate on the UK’s statutory drug pricing scheme as a way of drawing attention to the need for a voluntary price deal that can revive the international competitiveness of the life science industry.
Older Medicines Rebate Will Test UK’s New Pricing & Access Scheme
As the UK government implements a new rebate system for older medicines as part of the new pricing deal, industry trade bodies and experts suggest that exceptions will have to be made, such as higher prices or lower rebate levels for specific products.